ヘリオス
4593
東証グロース
医薬品
ヘリオスの決算推移
損益計算書
（単位：百万円）
2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
|---|---|---|---|---|---|---|---|---|---|
売上高 | 98 | 77 | 27 | N/A | N/A | 27 | 41 | 90 | 121 |
売上原価 | 9 | 9 | 3 | N/A | N/A | N/A | N/A | N/A | 13 |
売上総利益 | 88 | 68 | 24 | N/A | N/A | 27 | 41 | 90 | 109 |
販管費 | 1,149 | 3,575 | 2,372 | 5,063 | 4,271 | 1,239 | 1,722 | 1,449 | 1,184 |
営業利益 | -1,061 | -3,508 | -2,349 | -5,063 | -4,271 | -4,183 | -5,384 | -5,179 | -3,379 |
営業外収益 | 148 | 116 | 16 | 8 | 7 | N/A | N/A | N/A | N/A |
営業外費用 | 75 | 36 | 82 | 30 | 240 | N/A | N/A | N/A | N/A |
経常利益 | -988 | -3,427 | -2,415 | -5,085 | -4,504 | N/A | N/A | N/A | N/A |
特別利益 | 28 | 0 | 643 | 1 | 100 | N/A | N/A | N/A | N/A |
特別損失 | N/A | N/A | N/A | 7 | N/A | N/A | N/A | N/A | N/A |
当期純利益 | -959 | -3,434 | -1,777 | -5,097 | -4,410 | -5,512 | -4,910 | -5,169 | -3,823 |
貸借対照表
（単位：百万円）
2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
|---|---|---|---|---|---|---|---|---|---|
資産 | 10,487 | 9,174 | 19,696 | 14,980 | 21,101 | 23,171 | 23,971 | 15,033 | 15,155 |
流動資産 | 9,325 | 8,073 | 19,288 | 12,326 | 18,538 | 15,007 | 16,429 | 8,462 | 7,683 |
現金及び預金 | 9,195 | 7,826 | 19,040 | 11,627 | 17,946 | 13,923 | 15,126 | 7,247 | 6,722 |
売上債権 | 21 | 19 | N/A | N/A | N/A | 264 | 400 | 292 | 324 |
棚卸資産 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
固定資産 | 1,162 | 1,101 | 408 | 2,653 | 2,562 | 8,165 | 7,543 | 6,571 | 7,471 |
負債 | 1,110 | 3,180 | 3,532 | 4,197 | 12,124 | 15,320 | 15,326 | 10,650 | 11,287 |
流動負債 | 1,080 | 772 | 1,300 | 1,623 | 597 | 2,686 | 6,042 | 3,808 | 5,169 |
仕入債務 | N/A | N/A | N/A | N/A | N/A | 435 | 359 | 281 | 229 |
固定負債 | 29 | 2,408 | 2,232 | 2,574 | 11,527 | 12,634 | 9,284 | 6,842 | 6,118 |
純資産 | 9,377 | 5,994 | 16,163 | 10,782 | 8,976 | 7,851 | 8,645 | 4,382 | 3,867 |
利益剰余金 | -1,390 | -4,824 | -6,600 | -11,697 | -16,107 | -2,218 | -2,692 | -2,386 | 1,665 |
自己株式 | N/A | N/A | N/A | 0 | 0 | 0 | -1 | -1 | -1 |